TRAIL expression in vascular smooth muscle

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 278, Issue 5 22-5, 2000, Pages

  Gochuico, Bernadette R ^a,b   Zhang, Jie ^a   Ma, Bei Yang ^a   Marshak Rothstein, Ann ^a   Fine, Alan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Apoptosis; Endothelial cell; Smooth muscle cell; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CYTOLYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VASCULAR SMOOTH MUSCLE;

EID: 0034085305     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.2000.278.5.l1045     Document Type: Article

References (32)

1. Adachi M, Suematsu S, Kondo T, Ogaswwara J, Yoshida N, and Nagata S. Targeted mutations in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Med 11: 294-300, 1995.
2. Berk JL, Franzblau CC, and Goldstein RH. Recombinant interleukin-1 beta inhibits elastin formation by a neonatal rat lung fibroblast phenotype. J Biol Chem 266: 3192-3197, 1991.
3. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, and Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 377: 630-632, 1995.
4. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
5. Campbell JH and Campbell GR. The cell biology of atherosclerosis B new developments. Aust NZ J Med 27: 497-500, 1997.
6. Chapman HA, Riese RJ, and Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59: 63-88, 1997.
7. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, and Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186: 1165-1170, 1997.
8. Fine A, Anderson NL, Williams MC, Rothstein TL, and Gochuico B. Fas expression in type II cells. Am J Physiol Lung Cell Mol Physiol 273: L64-L71, 1997.
9. Geng YJ, Wu Q, Muszynski M, Hansson GK, and Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 16: 19-27, 1996.
10. Gouchico BR, Miranda K, De Bie JJ, van Oosterhout AJM, Cruikshank WW, and Fine A. Fas ligand expression in murine airway epithelium: function and release during bronchial inflammation. Am J Physiol Lung Cell Mol Physiol 274: L444-L449, 1998.
11. Griffith TS, Brunner T, Fletcher SM, Green DR, and Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192, 1995.
12. Guevara NV, Kim HS, Antonova EI, and Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 3: 335-339, 1999.
13. Guo MW, Mori E, Xu JP, and Mori T. Identification of Fas antigen associated with apoptotic death in murine ovary. Biochem Biophys Res Commun 203: 1438-1446, 1994.
14. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stranger BZ, and Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448, 1995.
15. Kayagaki N, Wasasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino Y, Okumura K, and Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777-1783, 1995.
16. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, and Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994.
17. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri SM, Cohen GM, and Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272: 25417-25420, 1997.
18. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, and Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94: 1931-1936, 1997.
19. Mannick JB, Husladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, and Stamler JS. Fas-induced caspase denitrosylation. Science 284: 651-654, 1999.
20. Marianin SM and Krammer PH. Differential regulation of TRAIL and CD95b ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 28: 973-982, 1998.
21. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, and Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7: 1003-1006, 1997.
22. Pan G, Ni J, Wei YF, Yu GL, Gentz GR, and Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818, 1997.
23. Panoskaltsis-Mortari A and Bucy RP. In situ hybridization with digoxigenin RNA probes: facts and artifacts. Biotechniques 18: 300-307, 1995.
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 362: 801-809, 1993.
25. Rothstein TL, Wang JKM, Panka DJ, Foot LC, Wang Z, Stanger B, Cui H, Ju ST, and Marshak-Rothstein A. Protection against Fas-dependent, Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 374: 163-165, 1995.
26. Sayama K, Yonehara S, Watanabe Y, and Mild Y. Expression of Fas antigen in keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 103: 330-334, 1994.
27. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, and Tschopp J. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205-1213, 1998.
28. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, and Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 254: 439-459, 1998.
29. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker D, Wood WI, Goddard AD, Godowski P, and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-823, 1997.
30. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, and Nagata S. Fas ligand in human serum. Nat Med 2: 317-321, 1996.
31. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, and Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16: 5386-5397, 1997.
32. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, and Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.